With the current advancements in the understanding of the pathophysiology and treatment of HF (e.g. newly approved indication for SGLT2 inhibitors)46, the pharmacological armamentarium against HF may further expand in the coming years47. The gene discussed is SLC5A2; the disease is hydrops fetalis.